Abstract
Breast cancer is the commonest type of malignant tumor in women, comprising of about 30% of all cancers in women worldwide. In the past decades, the mortality of breast cancer patients has significantly been reduced due to the adoption of periodic breast cancer screening and the emergence of various treatments, such as radiotherapy, chemotherapy, and surgery. Currently, chemotherapy is one of the most effective treatments for breast cancer. Its side effects, however, pose a long-term challenge on a patient’s health. Thus, it is highly desirable to develop new therapies that can specifically target carcinoma cells without damaging normal and healthy cells. Tremendous efforts have been made to develop targeted drug delivery systems for breast cancer treatment. In this review, we intend to systematically examine recent progresses made along these directions. We highlighted various delivery carriers designed for directing the diffusion of therapeutic agents inside tumors to kill or suppress breast cancer cells. These carriers include molecular-recognitionelement modified anticancer agents, stem cells that have tropism to breast cancers, nanoparticle-based anticancer drugs, and anticancer peptides. In particular, we discussed recent patents on the new targeted therapeutic delivery systems, with an emphasis on triple-negative breast cancer therapies.
Keywords: Breast cancer, metastasis, stem cells, targeted drug delivery, treatment, tumor
Recent Patents on Anti-Cancer Drug Discovery
Title:Targeted Drug Delivery for Breast Cancer Treatment
Volume: 8 Issue: 2
Author(s): Sha Jin and Kaiming Ye
Affiliation:
Keywords: Breast cancer, metastasis, stem cells, targeted drug delivery, treatment, tumor
Abstract: Breast cancer is the commonest type of malignant tumor in women, comprising of about 30% of all cancers in women worldwide. In the past decades, the mortality of breast cancer patients has significantly been reduced due to the adoption of periodic breast cancer screening and the emergence of various treatments, such as radiotherapy, chemotherapy, and surgery. Currently, chemotherapy is one of the most effective treatments for breast cancer. Its side effects, however, pose a long-term challenge on a patient’s health. Thus, it is highly desirable to develop new therapies that can specifically target carcinoma cells without damaging normal and healthy cells. Tremendous efforts have been made to develop targeted drug delivery systems for breast cancer treatment. In this review, we intend to systematically examine recent progresses made along these directions. We highlighted various delivery carriers designed for directing the diffusion of therapeutic agents inside tumors to kill or suppress breast cancer cells. These carriers include molecular-recognitionelement modified anticancer agents, stem cells that have tropism to breast cancers, nanoparticle-based anticancer drugs, and anticancer peptides. In particular, we discussed recent patents on the new targeted therapeutic delivery systems, with an emphasis on triple-negative breast cancer therapies.
Export Options
About this article
Cite this article as:
Jin Sha and Ye Kaiming, Targeted Drug Delivery for Breast Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (2) . https://dx.doi.org/10.2174/1574892811308020003
DOI https://dx.doi.org/10.2174/1574892811308020003 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ErbB Antagonists Patenting: “Playing Chess with Cancer”
Recent Patents on Biotechnology Overcoming the Blood-Brain Barrier for Chemotherapy: Limitations, Challenges and Rising Problems
Anti-Cancer Agents in Medicinal Chemistry A Survey of Deep Learning Based Methods in Medical Image Processing
Current Signal Transduction Therapy Targeted Alpha Therapy with 213Bi
Current Radiopharmaceuticals Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment
Mini-Reviews in Medicinal Chemistry Cardio-Hepatic Metabolic Derangements and Valproic Acid
Current Clinical Pharmacology Trizbenzim, Cu-Trizbenzim and Zn-Trizbenzim as G-Quadruplex Inducing and Stabilizing Compounds on Human Telomeric Sequence and their Anticancer Properties
Anti-Cancer Agents in Medicinal Chemistry Neuroprotective Effects of Nonsteroidal Anti-inflammatory Drugs on Neurodegenerative Diseases
Current Pharmaceutical Design Prospective Plant Based Anticancer Lead Molecules
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluation of New imidazo[1,2-a]pyridine Derivatives as Selective COX-2 Inhibitors
Letters in Drug Design & Discovery The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency
Current HIV Research Site Targeted Press Coated Delivery of Methylprednisolone Using Eudragit RS 100 and Chitosan for Treatment of Colitis
Recent Patents on Anti-Infective Drug Discovery Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
Current Cancer Drug Targets Novel Drug Delivery System for Cancer Management: A Review
Current Cancer Therapy Reviews Effects of Edible Algae Polysaccharides on Allergic, Inflammatory, and Anti-Tumor Responses Through Toll-Like Receptor 4
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Advances in Ethnopharmacological and Toxicological Properties of Bioactive Compounds from <i>Aloe barbadensis</i> (Miller), <i>Aloe vera</i>
Current Bioactive Compounds DIMming Ovarian Cancer Growth
Current Drug Targets Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued)